Reviva Pharmaceuticals announced positive preliminary results from its Phase 3 RECOVER trial, showing that brilaroxazine effectively improved schizophrenia symptoms over one year, with a 18.6-point decrease in PANSS total scores and a 35% treatment discontinuation rate due to various reasons.